R&G PharmaStudies Co. Ltd. A
R&G PharmaStudies Co., Ltd. operates as a clinical trial outsourcing service provider in China and internationally. It provides drug clinical research and development integrated services. The company's services include clinical trial operation, clinical trial site management, biological sample testing, data management and statistical analysis, clinical trial consulting, and clinical pharmacology … Read more
R&G PharmaStudies Co. Ltd. A (301333) - Total Assets
Latest total assets as of June 2025: CN¥2.31 Billion CNY
Based on the latest financial reports, R&G PharmaStudies Co. Ltd. A (301333) holds total assets worth CN¥2.31 Billion CNY as of June 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
R&G PharmaStudies Co. Ltd. A - Total Assets Trend (2019–2024)
This chart illustrates how R&G PharmaStudies Co. Ltd. A’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
R&G PharmaStudies Co. Ltd. A - Asset Composition Analysis
Current Asset Composition (December 2024)
R&G PharmaStudies Co. Ltd. A's total assets of CN¥2.31 Billion consist of 91.3% current assets and 8.8% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 45.8% |
| Accounts Receivable | CN¥125.24 Million | 5.4% |
| Inventory | CN¥65.23 Million | 2.8% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥19.43 Million | 0.8% |
| Goodwill | CN¥85.60 Million | 3.7% |
Asset Composition Trend (2019–2024)
This chart illustrates how R&G PharmaStudies Co. Ltd. A's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: R&G PharmaStudies Co. Ltd. A's current assets represent 91.3% of total assets in 2024, an increase from 89.7% in 2019.
- Cash Position: Cash and equivalents constituted 45.8% of total assets in 2024, down from 61.3% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 3.0% of total assets, a decrease from 4.0% in 2019.
- Asset Diversification: The largest asset category is accounts receivable at 5.4% of total assets.
R&G PharmaStudies Co. Ltd. A Competitors by Total Assets
Key competitors of R&G PharmaStudies Co. Ltd. A based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
R&G PharmaStudies Co. Ltd. A - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - R&G PharmaStudies Co. Ltd. A generates 0.32x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Solid ROA - For every $100 in assets, R&G PharmaStudies Co. Ltd. A generates $6.00 in net profit.
R&G PharmaStudies Co. Ltd. A - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 5.52 | 5.45 | 2.44 |
| Quick Ratio | 5.33 | 5.29 | 2.24 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥1.73 Billion | CN¥ 1.66 Billion | CN¥ 351.81 Million |
R&G PharmaStudies Co. Ltd. A - Advanced Valuation Insights
This section examines the relationship between R&G PharmaStudies Co. Ltd. A's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.81 |
| Latest Market Cap to Assets Ratio | 0.11 |
| Asset Growth Rate (YoY) | 12.7% |
| Total Assets | CN¥2.34 Billion |
| Market Capitalization | $255.16 Million USD |
Valuation Analysis
Below Book Valuation: The market values R&G PharmaStudies Co. Ltd. A's assets below their book value (0.11 x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: R&G PharmaStudies Co. Ltd. A's assets grew by 12.7% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for R&G PharmaStudies Co. Ltd. A (2019–2024)
The table below shows the annual total assets of R&G PharmaStudies Co. Ltd. A from 2019 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥2.34 Billion | +12.65% |
| 2023-12-31 | CN¥2.07 Billion | +10.13% |
| 2022-12-31 | CN¥1.88 Billion | +177.96% |
| 2021-12-31 | CN¥677.47 Million | +26.31% |
| 2020-12-31 | CN¥536.36 Million | +20.03% |
| 2019-12-31 | CN¥446.86 Million | -- |